Achaogen Inc (AKAO) 13.74 $AKAO
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Achaogen to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 07, 4:31AM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 13 Annual Needham Healthcare Conference in New York, New York. Kenneth Hillan, Chief Executive Officer, and Derek Bertocci, Chief Financial Officer, are scheduled to present on Tuesday, April 8 at 10:40 a.m. ET, at the Westin NY Grand Central Hotel.
Achaogen Appoints Chris Boerner to Board of Directors
GlobeNewswire - Wed Apr 02, 4:30AM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that Dr. Chris Boerner has joined Achaogen's Board of Directors. Dr. Boerner currently serves as Executive Vice President, Commercial for Seattle Genetics, Inc., a publicly traded biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer.
Achaogen Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option to Purchase Additional Shares
GlobeNewswire - Mon Mar 17, 10:56AM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the closing of its initial public offering of 6,900,000 shares of its common stock at a price to the public of $12.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock to cover over-allotments, resulting in aggregate gross proceeds of $82,800,000, before underwriting discounts, commissions and estimated offering expenses. Achaogen's common stock is listed on The NASDAQ Global Market under the ticker symbol "AKAO."
Achaogen Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Mar 12, 4:30AM CDT
Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $12.00 per share. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "AKAO" on March 12, 2014. In addition, Achaogen has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on March 17, 2014, subject to customary closing conditions.
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Achaogen to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 07, 4:31AM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 13 Annual Needham Healthcare Conference in New York, New York. Kenneth Hillan, Chief Executive Officer, and Derek Bertocci, Chief Financial Officer, are scheduled to present on Tuesday, April 8 at 10:40 a.m. ET, at the Westin NY Grand Central Hotel.
Achaogen Appoints Chris Boerner to Board of Directors
GlobeNewswire - Wed Apr 02, 4:30AM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that Dr. Chris Boerner has joined Achaogen's Board of Directors. Dr. Boerner currently serves as Executive Vice President, Commercial for Seattle Genetics, Inc., a publicly traded biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer.
Achaogen Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option to Purchase Additional Shares
GlobeNewswire - Mon Mar 17, 10:56AM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the closing of its initial public offering of 6,900,000 shares of its common stock at a price to the public of $12.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock to cover over-allotments, resulting in aggregate gross proceeds of $82,800,000, before underwriting discounts, commissions and estimated offering expenses. Achaogen's common stock is listed on The NASDAQ Global Market under the ticker symbol "AKAO."
Achaogen Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Mar 12, 4:30AM CDT
Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $12.00 per share. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "AKAO" on March 12, 2014. In addition, Achaogen has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on March 17, 2014, subject to customary closing conditions.
